Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6553561 | 0.83 | CD274 (0.49) | GPR119KEAP1NFE2L2CD274KDM1A | |
| SCHEMBL7442140 | 0.82 | F2 (0.48) | — | |
| SCHEMBL7546740 | 0.80 | MAPT (0.51) | GPR119MAPTKEAP1NFE2L2POLB | |
| Hydrochloric Acid SCHEMBL6554475 | 0.79 | SLC6A2 (0.44) | — | |
| SCHEMBL29097854 | 0.71 | ESR2 (0.56) | KEAP1NFE2L2CD274MAOAMAOB | |
| SCHEMBL30199503 | 0.71 | ESR2 (0.56) | KEAP1NFE2L2CD274MAOAMAOB | |
| SCHEMBL14507098 | 0.70 | SLC6A4 (0.55) | MAPTKDM1AALDH1A1MEN1KMT2A | |
| SCHEMBL17276773 | 0.70 | ALDH1A1 (0.72) | MAPTKDM1AALDH1A1POLBMEN1 | |
| SCHEMBL4402074 | 0.70 | KDM1A (0.46) | GPR119MAPTKEAP1NFE2L2KDM1A | |
| SCHEMBL6553403 | 0.69 | MAOB (0.52) | MAPTMAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883405-B1 | AMIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6414020-B2 | ANTIPROTEOLYTIC AMIDINO OR DERIVATIVE USEFUL FOR TREATING PENCREATITIS, THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS, EMPHYSEMA OR INFLAMMATION | 3- DIMENSIONAL PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20010025041-A1 | Amidino protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-27 | — | — | US | disclosed |
| US-6281206-B1 | AMIDINO AND BENZAMIDINO COMPOUNDS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-08-28 | — | — | US | disclosed |
| US-6225302-B1 | Amidino protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-01 | — | — | US | disclosed |
| US-6133315-A | ADMINISTERING TO TREAT PANCREATITIS, THROMBOSIS, ISCHEMIA, STROKE, RESTENOSIS, EMPHYSEMA OR INFLAMMATION IN A MAMMAL; COMPOUNDS SUCH AS 2-CHLOROBENZENESULFONIC ACID 3-(3-AMIDINOPROPOXY)-5-METHYLPHENYL ESTER HYDROCHLORIDE | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6034127-A | CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0883405-A4 | AMIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0883405-A1 | AMIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997024135-A1 | AMIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025041-A1 | Amidino protease inhibitors | CTRL, PEPD, PRSS3 | GPR119 1171/4885MAPT 3392/4885KEAP1 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.